Maine News Reporter

DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of GERD, historical and forecasted epidemiology, as well as the market trends in the United States, EU4, the United Kingdom, and Japan.

Interested to know which GERD therapies will capture the highest market share? Request for unlocking the Sample Page of the “GERD Market Insights” – https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the GERD Market Report

• The United States GERD market size was valued at approximately USD 3,400 million in 2025 and is projected to reach nearly USD 5,700 million by 2036, growing at a CAGR of 6% during the forecast period from 2026 to 2036.

• The United States accounted for the largest share of the 7MM market, reaching approximately USD 3,400 million in 2025.

• Chronic use of PPIs is associated with concerns around nutrient malabsorption, renal effects, and potential microbiome alterations, with many patients remaining on prolonged therapy without clear indications.

• The GERD landscape demonstrates a pronounced age-related gradient, with disease burden peaking in the elderly population; in the United States, patients aged ≥60 years account for approximately 50% of total cases in 2025.

• Linaprazan glurate (X842) and Tegoprazan (BLI5100) represent key pipeline candidates expected to diversify the market by 2036, aiming to offer improved durability and faster symptom relief.

• The treatment paradigm remains heavily dominated by Proton Pump Inhibitors (PPIs); however, the landscape is gradually evolving with the emergence of Potassium-Competitive Acid Blockers (P-CABs), such as VOQUEZNA.

• The emergence of novel oral formulations is expected to improve patient compliance and overall treatment outcomes.

• EU4 and the UK together account for approximately 74 million prevalent GERD cases in 2025.

• A consistent female predominance is observed across regions; in the US, females account for 60% of cases in 2025, while in EU4 and the UK, they represent approximately 55%.

• Non-Erosive Reflux Disease (NERD) is the most common presentation, accounting for approximately 70% of all GERD cases, with the remaining 30% classified as Erosive Esophagitis in the US in 2025.

Gain a competitive edge in the GERD Market by exploring our in-depth analysis @ GERD Market Report – https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

GERD Market Overview

Gastroesophageal Reflux Disease (GERD) is a chronic, relapsing condition characterized by the reflux of gastric contents into the esophagus, leading to symptoms such as heartburn, regurgitation, chest discomfort, and potential mucosal injury. In the US, GERD remains one of the most prevalent Gastrointestinal (GI) disorders, significantly impacting quality of life and driving high utilization of primary care, gastroenterology consultations, OTC products, and prescription therapies.

Diagnosis remains challenging, as no single test defines GERD. Evaluation relies on symptom assessment, esophagogastroduodenoscopy (EGD), and pH-impedance monitoring for patients with atypical or refractory symptoms. Many patients self-medicate using OTC PPIs or antacids without diagnostic workup, delaying optimized therapy and obscuring true disease severity in real-world data.

Factors Driving the Growth of the GERD MarketRising Prevalence of Gastroesophageal Reflux Disease (GERD)

Increasing cases linked to obesity, unhealthy dietary habits, sedentary lifestyles, and aging populations are driving market demand.

Growing Adoption of Advanced Therapies

The introduction of novel acid suppression therapies, potassium-competitive acid blockers (P-CABs), and minimally invasive treatment options is expanding the GERD treatment landscape.

Increasing Awareness and Diagnosis Rates

Greater patient awareness and improved diagnostic procedures are supporting earlier detection and long-term disease management.

Strong Demand for Long-Term Symptom Management

The chronic and recurrent nature of GERD continues to increase the need for effective maintenance therapies and personalized treatment approaches.

Expanding Healthcare Access and Research Activities

Rising healthcare expenditure, favorable reimbursement support, and ongoing clinical research into next-generation GERD therapies are contributing to market growth.

GERD Market Segment Analysis

Clinical segmentation reveals that Non-Erosive Reflux Disease (NERD) is the most common presentation, accounting for approximately 70% of all GERD cases. The remaining 30% are classified as Erosive Esophagitis in the US in 2025. The market is further segmented by Region/Geographies and Drugs/Therapies, with analyses covering addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, attribute analysis, and unmet need.

GERD Market Regional AnalysisThe United States is Expected to Dominate the Overall GERD Market

As per DelveInsight’s analysis, the United States accounted for the largest share of the 7MM market, reaching approximately USD 3,400 million in 2025. The GERD prevalent population represents a massive disease burden, with EU4 and the UK accounting for approximately 74 million cases in 2025.

The report covers geographies including North America (the US), Europe (Germany, France, Italy, Spain, and the UK), and Asia-Pacific (Japan).

GERD Key Players, Market Leaders and Emerging Companies

GERD Companies include: Braintree Laboratories Cinclus Pharma Phathom And Others.

Download the report to understand which factors are driving GERD Market Trends –

Latest Highlights from the GERD Market

• In November 2025, Cinclus Pharma advanced into late-stage development with the launch of its first Phase III trial, and patient enrollment is progressing as planned; topline data are anticipated in the second half of 2026 and could serve as a major value catalyst for the company.

• In August 2025, Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, reported positive topline results from the 24-week maintenance phase of the pivotal Phase III TRIUMpH study evaluating tegoprazan, a novel P-CAB, for the treatment of GERD.

• In July 2024, Phathom Pharmaceuticals announced that the US FDA had approved VOQUEZNA (vonoprazan) 10 mg tablets for the relief of heartburn associated with nonerosive GERD in adults.

Discover key developments and opportunities in the GERD Market @ GERD Market Size

GERD Market Outlook

Gastroesophageal Reflux Disease (GERD) is a chronic, relapsing gastrointestinal disorder characterized by the reflux of gastric contents into the esophagus, leading to symptoms such as heartburn, regurgitation, chest discomfort, and mucosal injury. Across the EU4 and the UK, GERD represents a substantial public health burden, significantly impairing quality of life and driving high utilization of primary care services, gastroenterology consultations, OTC medications, and long-term prescription therapies.

Scope of the GERD Market Report

Study Period: 2022–2036

Historical Year: 2022–2025

Forecast Period: 2026–2036

Geographies Covered: North America (the US); Europe (Germany, France, Italy, and Spain, and the UK); Asia-Pacific (Japan)

Market CAGR (the US): 6% (2022–2036)

Major GERD Companies: Braintree Laboratories, Cinclus Pharma, Phathom, and others.

Market Segments Covered: Region/Geographies, Drugs/Therapies

Key Focus Areas: Addressable Patient Population, Market Drivers and Barriers, Cost Assumptions and Pricing Analogues, KOL Views, SWOT Analysis, Reimbursement, Attribute Analysis, and Unmet Need

Table of Contents

1. Key Insights

2. Report Introduction

3. GERD Market Overview at a Glance

4. Epidemiology and Market Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Patient Journey

10. Epidemiology and Patient Population

11. Marketed Therapies

12. Emerging Therapies

13. GERD: Market Analysis

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

How DelveInsight’s GERD Market Report Helps CXOs and Business Leaders

• Evaluate current and future market opportunities across the United States, EU4, the United Kingdom, and Japan through comprehensive market forecasts and regional growth trend analysis.

• Benchmark leading GERD therapies, including Vonoprazan (VOQUEZNA), Linaprazan glurate (X842), and Tegoprazan (BLI5100), using detailed competitive intelligence and product profiling.

• Identify emerging growth opportunities by tracking pipeline candidates, clinical trial progress, and key industry developments, including the TRIUMpH study and recent FDA approvals.

• Assess the impact of anticipated regulatory approvals, reimbursement policies, and product launches on market share, pricing strategies, and therapy adoption.

• Support strategic decision-making with insights into KOL perspectives, unmet diagnostic and treatment needs, patient stratification strategies, and evolving market dynamics within the GERD landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Abhishek kumar
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market